Congenital Myasthenic Syndrome 18 (CMS18) — Comprehensive Research Report

Important Nomenclature Note (Read First)

Searches for "Congenital Myasthenic Syndrome 18/CMS18" frequently surface material on COL13A1, but that gene causes a different, higher-numbered entity — Congenital Myasthenic Syndrome 19 (CMS19, OMIM #616720) — not CMS18. This is a common confusion because the numbering is easy to mistransc­ribe and because COL13A1-CMS dominates recent CMS literature volume.

CMS18 is the SNAP25-related disorder, OMIM #616330, originally named "Myasthenic syndrome, congenital, 18, with intellectual disability and ataxia" and gene symbol SNAP25 (synaptosome-associated protein 25, 20p12.2). OMIM's clinical synopsis for this entry has since been folded into/relabeled "Developmental and Epileptic Encephalopathy 117" (DEE117) as the phenotypic spectrum of SNAP25 heterozygous variants was found to extend beyond myasthenia into a broader neurodevelopmental/epileptic encephalopathy continuum. MedGen (Concept ID C4225364) still lists "Congenital myasthenic syndrome 18" as a synonym/legacy label for the same OMIM #616330 entity, and the disease is also cataloged under HGNC gene aliases RIC-4, SEC9, SUP, SNAP for the SNAP25 protein. This report treats CMS18 = SNAP25-related presynaptic CMS/DEE (OMIM #616330) throughout, and flags where source material blends into the wider DEE117 phenotype.

1. Disease Information

Overview: CMS18 is a rare, autosomal-dominant presynaptic congenital myasthenic syndrome caused by heterozygous (typically de novo) missense or truncating variants in SNAP25, a core SNARE-complex protein required for calcium-triggered synaptic vesicle exocytosis. Unlike the majority of CMS subtypes — which are autosomal recessive and confined to the neuromuscular junction (NMJ) — CMS18 is dominant and produces a combined phenotype of fatigable myasthenic weakness plus CNS dysfunction (cortical hyperexcitability/epilepsy, cerebellar ataxia, and intellectual disability), reflecting SNAP25's essential role in exocytosis at both the NMJ and central synapses.

Key identifiers: - OMIM #616330 — "Myasthenic syndrome, congenital, 18, with intellectual disability and ataxia" / "Developmental and epileptic encephalopathy 117; DEE117" - OMIM gene entry *600322 — SNAP25 (Synaptosomal-Associated Protein, 25-KD) - MedGen: C4225364 ("Congenital myasthenic syndrome 18") - HGNC: SNAP25, HGNC:11132; cytogenetic location 20p12.2 - NCBI Gene ID: 6616 - Gene aliases: SNAP-25, RIC-4, RIC4, SEC9, SUP - Orphanet: listed under the broader "Congenital myasthenic syndrome" grouping (ORPHA:590); a dedicated presynaptic-CMS/SNAP25 stub is cross-referenced under the mechanistic Orphanet grouping for defective synaptic vesicle cycling - Frequency in the CMS spectrum: <1% of all genetically solved CMS cases — among the rarest presynaptic CMS subtypes (GeneReviews Congenital Myasthenic Syndromes Overview, NBK1168)

Synonyms: CMS18; SNAP25-related congenital myasthenic syndrome; Myasthenic syndrome, congenital 18, with intellectual disability and ataxia; Developmental and epileptic encephalopathy-117 (DEE117); SNAP25 encephalopathy

Data provenance: Knowledge is derived almost entirely from individual published case reports/series (fewer than 10-15 molecularly confirmed patients described to date across the founding 2014 report, subsequent DEE-focused cohorts, and isolated case reports) plus mechanistic biophysical/cell-biology studies of the specific mutant alleles — not from large aggregated disease registries. This is characteristic of an ultra-rare, recently delineated Mendelian disorder.

2. Etiology

Primary cause: Heterozygous, almost always de novo, missense or nonsense variants in SNAP25, encoding a t-SNARE protein essential for synaptic vesicle docking, priming, and calcium-triggered fusion at both the presynaptic motor nerve terminal and central synapses.

Genetic risk factors / mechanism of pathogenicity: - Dominant-negative mechanism is well established for the founding mutation (I67N): mutant SNAP25B protein incorporates into SNARE complexes and destabilizes/poisons them even in the presence of wild-type protein, rather than simply reducing gene dosage (haploinsufficiency). - SNAP25 is under strong evolutionary and population constraint consistent with the dominant, de novo disease mechanism — gnomAD-type constraint metrics for genes causing severe dominant neurodevelopmental disease from de novo variants typically show high missense and loss-of-function intolerance (elevated missense Z-score / pLI), consistent with SNAP25 being depleted of both truncating and disruptive missense variation in the general population (per general gnomAD constraint methodology; Wilfert et al., gene-constraint/genotype-phenotype correlation studies, PMC10340126). - No recessive/biallelic SNAP25 CMS has been reported — inheritance is monogenic autosomal dominant with each reported case arising as a de novo event in an otherwise unaffected family (no vertical transmission reported to date, consistent with the severity of the phenotype limiting reproductive fitness).

Environmental/other risk factors: None identified — this is a monogenic disorder with no known environmental, infectious, or lifestyle contribution to disease occurrence. No consanguinity signal (dominant de novo mechanism).

Protective factors: None specifically described. No modifier alleles have been reported; phenotypic variability across the small number of known cases appears driven by variant-specific biophysical mechanism (see Section 6) rather than by identified genetic modifiers.

Gene-environment interactions: Not applicable/not described — no evidence of environmental triggers modifying expressivity has been reported in the literature.

3. Phenotypes

CMS18/SNAP25-CMS phenotypes span neuromuscular (myasthenic), central neurological (epileptic encephalopathy, ataxia), and neurodevelopmental domains, distinguishing it from isolated CMS subtypes.

Core neuromuscular (myasthenic) phenotypes

Central/CNS phenotypes

Phenotype characteristics

• Age of onset: Ranges from prenatal/neonatal (severe cases — decreased fetal movement, arthrogryposis, birth respiratory failure) to infancy/early childhood (typical presenting age for the myasthenia-ataxia-ID triad) to later childhood-onset seizures (index patient, seizure onset ~age 5).
• Severity: Highly variable — from a lethal neonatal presentation (the Gln177Ter nonsense-variant patient died on day 6 of life from respiratory failure) to a moderate, largely stable phenotype persisting into the third decade (D166Y patient, 23 years old at report).
• Progression: Neurological features (ataxia, ID) are generally static/developmental rather than progressive once established, though epilepsy course is variable (the index patient's seizures were described across a multi-year follow-up with variable anticonvulsant response).
• Frequency among affected individuals: Given the very small number of published cases (literature currently comprises roughly the I67N index case, the Q177Ter neonatal case, and the V48F/D166Y encephalopathy-predominant cases characterized functionally in the 2024 eLife paper, plus additional unpublished/registry cases alluded to in reviews), formal phenotype-frequency percentages analogous to HPO annotation frequencies are not established — most features are reported as present/absent per-case rather than as population frequencies.

Quality-of-life impact: Not formally measured with QOL instruments (no EQ-5D/SF-36/PROMIS data identified); qualitatively, the combination of motor weakness, ataxia, and intellectual disability in surviving patients produces substantial functional impairment (non-ambulation or impaired gait, poor/absent speech, dependence for activities of daily living reported in the more severely affected cases per the DEE117 OMIM synopsis).

4. Genetic/Molecular Information

Causal gene: SNAP25 (Synaptosomal-Associated Protein, 25kDa), OMIM 600322, chromosome 20p12.2, HGNC:11132, NCBI Gene ID 6616. Two alternatively spliced isoforms exist — SNAP25a and SNAP25b* — differing in a short internal segment; SNAP25b is the predominant adult neuronal isoform and is the isoform in which the founding I67N mutation was characterized.

Reported pathogenic variants (heterozygous, all reported as de novo):

Variant type/class: Missense (I67N, V48F, D166Y, G86R) and nonsense/truncating (Q177Ter) — no large structural rearrangements or splice-site variants reported for CMS18/SNAP25-CMS to date.

Allele frequency in population databases: Given the extreme rarity and de novo, severe-phenotype dominant mechanism, these specific pathogenic variants are absent or present only as extremely rare singletons in gnomAD/population databases — consistent with strong negative selection against SNAP25 coding variation in the general population (SNAP25 shows population-level constraint against both loss-of-function and disruptive missense variation, per gnomAD gene-constraint conventions).

Somatic vs. germline origin: All molecularly reported cases are germline, de novo, heterozygous variants (not somatic mosaicism in the parents; though within the patient, the index I67N case's electrophysiology showed non-normally distributed quantal-content values that the authors interpreted as possibly reflecting somatic mosaicism at the neuromuscular junction level — an intriguing but not independently confirmed observation).

Functional consequences by variant (loss-of-function vs. gain-of-function vs. dominant-negative): - I67N — classic dominant-negative: destabilizes the SNARE four-helix bundle via loss of a critical hydrophobic packing interaction (replacing hydrophobic Ile [hydropathy +4.5] with hydrophilic Asn [-3.5]); in reconstituted membrane-fusion assays, mutant SNAP25B blocked calcium-triggered v-SNARE/t-SNARE liposome fusion, and cotransfection of mutant with wild-type in chromaffin cells reduced catecholamine release to 11% of wild-type levels, confirming a poisoning/dominant-negative effect on the assembled complex rather than simple haploinsufficiency. - V48F and D166Y — mechanistically distinct "neomorphic" mutations combining loss-of-function (impaired synaptotagmin-1 interaction, reduced Ca²⁺-stimulated fusion, reduced readily-releasable-pool priming) with gain-of-function features (paradoxically enhanced SNARE-partner binding, increased spontaneous release, lowered energy barrier for fusion, and evasion of complexin-mediated fusion clamping) — as characterized in detailed reconstituted-fusion biophysics (eLife 2024, PMID 38411501). - Q177Ter — C-terminal truncation predicted to disrupt the SNARE motif and membrane-proximal region required for complex assembly/stability; associated with the most severe reported phenotype (neonatal lethality).

Modifier genes: None identified/reported.

Epigenetic information: Not reported for this disorder.

Chromosomal abnormalities: Not applicable — CMS18 arises from single-nucleotide/small coding variants in SNAP25, not from copy-number or structural chromosomal changes. (Note: SNAP25 also lies within a chromosomal region relevant to unrelated 20p microdeletion contexts, but that is mechanistically distinct from the point-mutation CMS18/DEE117 disease model and outside this report's scope.)

Suggested ontology bindings: Gene — hgnc:11132 (SNAP25); Molecular function — GO:0005484 (SNARE binding), GO:0061789 (SNARE complex disassembly, if relevant to disassembly-cycle mechanism), GO:0016081 (synaptic vesicle docking); relevant GO Cellular Component — GO:0031201 (SNARE complex), GO:0042734 (presynaptic membrane), GO:0008021 (synaptic vesicle).

5. Environmental Information

Not applicable — no environmental toxins, occupational exposures, radiation, pollution, lifestyle, or infectious triggers are implicated in CMS18 causation. This is a purely genetic (de novo monogenic) disorder. No gene-environment interaction data exist.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger (upstream): Heterozygous de novo SNAP25 variant produces a structurally altered t-SNARE protein (I67N: destabilized coiled-coil; V48F/D166Y: altered synaptotagmin-1-binding interface; Q177Ter: truncated protein).
2. SNARE complex assembly/stability defect: Mutant SNAP25 protein incorporates into the ternary SNARE complex (with syntaxin-1 and VAMP2/synaptobrevin-2) alongside wild-type SNAP25, producing either (a) a destabilized, dominant-negative complex with an increased energy barrier to membrane fusion (I67N), or (b) an aberrantly hyperstable/miswired complex with disrupted synaptotagmin-1 coupling and dysregulated calcium sensing (V48F, D166Y).
3. Impaired calcium-triggered synaptic vesicle exocytosis: Across all characterized variants, calcium-stimulated, synchronous vesicle fusion is compromised — manifesting as reduced evoked quantal release (reduced miniature endplate potential frequency and quantal content at the NMJ) and, in reconstituted central-synapse systems, altered readily-releasable-pool size, altered spontaneous (miniature) release, and altered fusion kinetics.
4. Presynaptic neuromuscular transmission failure: At the motor endplate, this produces the electrophysiological signature of a presynaptic CMS — reduced quantal release with normal postsynaptic acetylcholine receptor density/distribution and normal synaptic vesicle docking morphology (docked vesicles are present but fail to fuse efficiently) — yielding fatigable muscle weakness, ptosis, and (in severe cases) neonatal respiratory failure and arthrogryposis from reduced fetal muscle activity.
5. Central synaptic transmission failure: The same SNARE-complex defect operating in CNS neurons (cortical, cerebellar) produces network-level dysfunction: cortical hyperexcitability/epileptogenesis (paradoxically, impaired inhibitory/excitatory balance from dysregulated vesicle release can manifest as seizures), cerebellar Purkinje/granule-cell circuit dysfunction (ataxia), and impaired synaptic plasticity/circuit maturation underlying intellectual disability and developmental delay.
6. Downstream systemic consequences: Chronic impaired neuromuscular and CNS synaptic function drives the multisystem phenotype — feeding difficulty, hypotonia, contractures/arthrogryposis (reduced in utero movement), and the neurodevelopmental/epilepsy phenotype.

Which mechanisms are upstream vs. downstream: The single unifying upstream lesion is impaired SNARE-complex-mediated, calcium-triggered vesicle fusion; everything else (myasthenic weakness, ataxia, seizures, ID) is a downstream tissue-specific consequence of this one presynaptic mechanism operating in different neuronal populations (motor nerve terminal vs. cortex vs. cerebellum).

Cell types involved (CL terms): - Motor neuron / neuromuscular junction presynaptic terminal — CL:0000100 (motor neuron) - Cortical excitatory/inhibitory neurons — CL:0000598 (pyramidal neuron), CL:0000617 (GABAergic interneuron, if inhibitory dysfunction contributes to hyperexcitability) - Cerebellar Purkinje cells — CL:0000121 (Purkinje cell) - Skeletal muscle fiber (postsynaptic target, secondarily affected) — CL:0000188/CL:0008002

Biological processes (GO terms): - GO:0016079 — synaptic vesicle exocytosis - GO:0031629 — synaptic vesicle fusion to presynaptic active zone membrane - GO:0007269 — neurotransmitter secretion - GO:0099525 — presynaptic dense core vesicle exocytosis (relevant given SNAP25's dual role in synaptic and dense-core-vesicle release) - GO:0060079 — excitatory postsynaptic potential (downstream circuit effect)

Protein dysfunction: Predominantly dominant-negative destabilization (I67N) or neomorphic gain/loss-of-function combination (V48F, D166Y) rather than simple loss-of-function/haploinsufficiency — an important mechanistic nuance versus most recessive LOF-driven CMS genes.

Biochemical abnormalities: Core defect is in the SNARE (soluble NSF-attachment protein receptor) fusion machinery — SNAP25 is the t-SNARE partner of syntaxin-1 (plasma membrane) and VAMP2/synaptobrevin (vesicle membrane); disease variants disrupt either the coiled-coil zippering of the four-helix SNARE bundle or the calcium-sensor (synaptotagmin-1) coupling interface required to convert calcium influx into fast, synchronous fusion.

Molecular/omics profiling: No transcriptomic, proteomic, or metabolomic disease-tissue profiling has been published for human CMS18 patients (tissue inaccessibility in a rare pediatric neuromuscular/CNS disorder); mechanistic insight instead comes from reconstituted biochemical fusion assays (liposome fusion, single-vesicle content-mixing assays), chromaffin-cell exocytosis assays, and electrophysiological recordings from patient intercostal-muscle endplates (microelectrode studies).

Advanced technologies: No single-cell, spatial transcriptomic, or CRISPR screen data specific to human CMS18 tissue have been published. Functional dissection has instead relied on classic single-molecule/reconstitution biophysics (eLife 2024 study) and expression-system electrophysiology (PC12/chromaffin cells, cultured neurons).

7. Anatomical Structures Affected

Organ level: - Primary: Peripheral nervous system — the neuromuscular junction (motor nerve terminal) and skeletal muscle (secondarily, via impaired innervation); central nervous system — cerebral cortex (epileptogenesis), cerebellum (ataxia). - Secondary: Respiratory system (via bulbar/respiratory muscle weakness — the most life-threatening secondary organ involvement, causing neonatal respiratory failure in the severe case); musculoskeletal system (contractures/arthrogryposis, clubfeet from reduced fetal movement); orofacial structures (cleft palate, micrognathia reported in the severe neonatal case, likely also secondary to reduced fetal orofacial muscle activity/deformation). - Body systems involved: Neuromuscular, nervous (central and peripheral), musculoskeletal, and (secondarily, in severe neonatal cases) respiratory.

Tissue and cell level: - Presynaptic nerve terminal (motor and central neurons) — UBERON:0000102 (motor neuron / axon terminal, general presynaptic terminal concept) - Skeletal muscle motor endplate — UBERON:0031594 (neuromuscular junction) if using an anatomical descriptor - Cerebral cortex — UBERON:0000956 - Cerebellum — UBERON:0002037 - Cell populations: motor neurons, cortical pyramidal/interneurons, cerebellar Purkinje and granule cells (see CL terms above)

Subcellular level: - Synaptic vesicle membrane — GO:0008021 (synaptic vesicle) - Presynaptic plasma membrane — GO:0042734 - SNARE complex assembly — GO:0031201 (SNARE complex)

Localization: - Site of primary pathology: presynaptic nerve terminal at both the neuromuscular junction and central synapses (UBERON:0031594 NMJ; cortex/cerebellum for CNS involvement). - Lateralization: Not applicable/no lateralized pattern reported — disease is a diffuse/generalized presynaptic transmission defect (bilateral ptosis, generalized weakness, diffuse cortical/cerebellar dysfunction), not a focal or unilateral process.

8. Temporal Development

Onset: - Typical age of onset: Congenital/neonatal to early childhood. The most severe reported case (Q177Ter) presented prenatally (polyhydramnios, decreased fetal movement) with birth at 35 weeks and immediate respiratory failure. The founding index case (I67N) had an earlier developmental/myasthenic presentation with seizure onset around age 5. The V48F and D166Y cases were characterized as adolescent/young-adult at time of report (15 and 23 years old respectively) with seizure onset in infancy (5 months) for V48F. - Onset pattern: Predominantly congenital/insidious for the myasthenic/hypotonic component (present from birth), with acute-onset possible for the most severe respiratory presentations, and a more subacute/progressive unmasking of the epileptic-encephalopathy component over the first years of life.

Progression: - Disease stages: Not formally staged (no consensus staging system exists for this ultra-rare disorder). - Progression rate/course pattern: Variable and not uniformly progressive — the neurodevelopmental/ataxic component appears largely static once established (a developmental disorder rather than a neurodegenerative one), while epilepsy course fluctuates (index patient's seizures were treatment-resistant for a period, then apparently better controlled). The disease course is best described as "static-to-fluctuating" rather than classically progressive or classically episodic. - Disease duration: Chronic, lifelong in survivors; the most severely affected neonatal patient died on day 6 of life (respiratory failure) — indicating the phenotype spans from neonatal-lethal to a chronic, non-degenerative lifelong neurodevelopmental/myasthenic disorder.

Patterns: - Remission: No spontaneous remission reported; myasthenic component may show partial pharmacologic improvement (index case: neostigmine partially reduced EMG decrement). - Critical periods: The perinatal/neonatal period represents the highest-risk critical window (respiratory failure risk in severe truncating variants); early childhood is the critical window for seizure onset and developmental-trajectory determination.

9. Inheritance and Population

Epidemiology: - Prevalence/incidence: Not formally estimated — CMS18/SNAP25-CMS is one of the rarest genetically defined CMS subtypes, representing <1% of all molecularly solved CMS cases (GeneReviews CMS Overview, NBK1168). Given that CMS overall has an estimated prevalence on the order of 1-9 per 1,000,000 (typical Orphanet-class range for the broader CMS group), SNAP25-CMS/CMS18 itself is almost certainly in the ultra-rare (<1 in 1,000,000) Orphanet prevalence band, with the world literature comprising a handful of published, molecularly confirmed cases.

Inheritance pattern: - Autosomal dominant (AD) — a notable exception among CMS genes, most of which are autosomal recessive. All reported cases have arisen as de novo heterozygous variants (suggested HP inheritance term: HP:0000006 Autosomal dominant, or more specifically HP:0025352 De novo — should be modeled with an Inheritance block bound to the relevant HPO mode-of-inheritance term, HP:0000006, with description noting the de novo pattern per case).

Penetrance: Presumed complete/high given that every reported carrier of a pathogenic SNAP25 variant manifests disease (consistent with the severe, dominant-negative/gain-of-function mechanism), though the very small case number precludes a formal penetrance estimate.

Expressivity: Highly variable — ranging from a mild-to-moderate ataxia/ID/epilepsy phenotype with long-term survival (D166Y, V48F, I67N cases) to a lethal neonatal arthrogrypotic/respiratory-failure phenotype (Q177Ter). This variability appears to track with the specific biophysical mechanism of each variant (dominant-negative destabilization vs. neomorphic gain/loss-of-function vs. truncation) rather than with any identified modifier.

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not formally documented in unaffected parents of reported cases (all cases described as apparently de novo with unaffected, non-mosaic-tested or presumed non-carrier parents); the index I67N patient's own quantal-release data showed a statistical pattern the authors speculated might reflect somatic mosaicism within the patient at the neuromuscular junction, though this remains an unconfirmed hypothesis specific to that case rather than a general germline-mosaicism finding.

Founder effects: None reported — each case has a distinct, apparently independently arising variant.

Consanguinity: Not relevant — dominant de novo mechanism, consistent with reported cases arising in non-consanguineous families (explicitly noted for the neonatal Q177Ter case).

Carrier frequency: Not applicable (not a recessive carrier-screening-relevant disorder; each case is an independent de novo dominant event, not inherited from a carrier parent).

Population demographics: No specific ethnic, geographic, or sex-ratio pattern has been established given the very small number of published cases (a mix of male and female patients reported: the index case was female, the neonatal lethal case was male). No geographic clustering reported.

10. Diagnostics

Clinical tests: - Electrophysiology (key diagnostic modality for presynaptic CMS): Repetitive nerve stimulation showing a decremental response; in vitro microelectrode studies of intercostal-muscle endplates in the index case demonstrated reduced miniature endplate potential (MEPP) frequency (31% of normal) and reduced quantal release probability (63% of normal) with preserved acetylcholine receptor density — the classic presynaptic quantal-release-defect signature distinguishing this CMS category from postsynaptic (e.g., AChR-deficiency) or synaptic-basal-lamina (e.g., COL13A1, COLQ) CMS subtypes. - EMG: Partial reduction of decrement with neostigmine reported in the index case, consistent with a component of neuromuscular junction dysfunction responsive to acetylcholinesterase inhibition, though the primary defect (presynaptic release) is not fully correctable by AChE inhibition. - EEG: Generalized polyspike-wave discharges documented in the index/seizure-affected cases; essential for characterizing the epileptic-encephalopathy component. - Brain MRI: Findings variably include mild diffuse cortical atrophy (D166Y case) and delayed myelination (V48F case); MRI can also be normal. - Muscle biopsy/ultrastructure: Electron microscopy in the index case showed abundant synaptic vesicles normally docked at active zones (i.e., a functional fusion defect, not a structural/vesicle-number defect — vesicles dock but fail to fuse efficiently), an important diagnostic/mechanistic distinguishing feature.

Genetic testing: - Recommended approach: Given the CMS phenotype-gene heterogeneity (>30 genes implicated in CMS) plus the possibility of a broader DEE, CMS gene-panel or exome/genome sequencing is the recommended diagnostic strategy rather than single-gene testing, given SNAP25's atypical (dominant, de novo, CNS-plus-NMJ) presentation that might not immediately suggest "classic CMS" to a clinician expecting recessive, NMJ-limited disease. - Rapid genome sequencing (rWGS): Explicitly demonstrated as diagnostically decisive in the critically ill neonatal case — a 7-day-turnaround rWGS identified the de novo SNAP25 c.529C>T (p.Gln177Ter) variant, illustrating the clinical utility of rapid sequencing in acutely ill neonates with an undifferentiated arthrogryposis/respiratory-failure presentation. - Single-gene testing: Available via clinical laboratories (e.g., NIH GTR lists dedicated SNAP25 sequence-analysis clinical tests for "Myasthenic syndrome, congenital, 18" — GTR test ID 581717) once the phenotype is suspected. - Chromosomal microarray/karyotype/FISH: Not primarily indicated (disease is due to point mutation, not structural rearrangement), though may be part of a standard undiagnosed-arthrogryposis or DEE diagnostic workup to exclude other etiologies. - Variant classification: Reported variants are classified pathogenic per functional/segregation evidence (de novo occurrence, absence from population databases, concordant electrophysiological/biochemical functional data) — consistent with ACMG/AMP criteria PS2 (de novo), PM2 (absent from population databases), PS3 (functional studies), and (for I67N) PM1/PM5-type structural-domain evidence.

Omics-based diagnostics: Not part of routine diagnostic workup; RNA-seq, proteomics, metabolomics not used clinically for this disorder.

Clinical criteria: No formal consensus diagnostic-criteria document specific to SNAP25-CMS exists; diagnosis rests on the combination of (1) fatigable myasthenic weakness with presynaptic electrophysiology, (2) epilepsy/cortical hyperexcitability, (3) ataxia, and (4) intellectual disability/developmental delay, confirmed by molecular identification of a heterozygous de novo pathogenic SNAP25 variant.

Differential diagnosis: Other presynaptic CMS genes (CHAT, SYT2, MUNC13-1/UNC13A, SLC5A7/choline transporter, VAMP1); other genetic causes of developmental and epileptic encephalopathy with ataxia (e.g., STXBP1-DEE, given STXBP1's mechanistic overlap as another SNARE-machinery regulator); other arthrogryposis-associated neuromuscular disorders in the severe neonatal presentation.

Screening: No population newborn-screening or carrier-screening program exists (ultra-rare, de novo dominant disorder not amenable to carrier screening); prenatal diagnosis could theoretically be offered in a family with a previously affected child (recurrence risk driven primarily by the low background rate of germline mosaicism rather than standard Mendelian recurrence risk, though this has not been specifically quantified for SNAP25).

11. Outcome/Prognosis

Survival and mortality: Highly variant-dependent. The Q177Ter truncating variant was associated with neonatal death on day 6 of life from respiratory failure following compassionate extubation. In contrast, patients with the I67N, V48F, and D166Y missense variants have survived into the second and third decades of life (ages 11, 15, and 23 years reported, respectively), indicating that survival is not uniformly poor and depends heavily on the specific variant's severity and the degree of respiratory/bulbar involvement.

Morbidity and function: Surviving patients experience chronic, non-fatal but substantial morbidity — non-fatigable ptosis in adulthood, ataxic gait (sometimes limited by contractures), dysarthria, and intellectual disability ranging from mild to severe with poor or absent speech in more affected individuals. No formal disability-outcome or QOL instrument data available.

Disease course/complications: Chronic contractures (knee flexion), recurrent/treatment-resistant seizures in a subset, and (in the index case) gradual improvement of muscle strength over time is notably not the typical CMS pattern reported for SNAP25 — data here are limited to case-level narrative rather than systematic follow-up. (Contrast: the COL13A1/CMS19 literature, not CMS18, specifically documents strength improvement into adulthood — care should be taken not to conflate the two entities' natural histories.)

Prognostic factors: The clearest identified prognostic determinant in the literature is variant-specific mechanism/severity — truncating/null-like variants (Q177Ter) associated with the most severe, neonatal-lethal phenotype; missense dominant-negative or neomorphic variants (I67N, V48F, D166Y) associated with survival and a chronic but non-degenerative course. No molecular biomarker-based prognostic model exists.

12. Treatment

Pharmacotherapy: - Acetylcholinesterase inhibitors (e.g., pyridostigmine, neostigmine): Standard first-line CMS therapy; in the index (I67N) patient, neostigmine partially reduced the EMG decremental response, indicating some benefit, though — as is typical for presynaptic CMS where the primary defect is release probability rather than receptor availability — benefit is expected to be partial rather than curative. - 3,4-Diaminopyridine (3,4-DAP): A potassium-channel blocker that increases acetylcholine release and prolongs the presynaptic action potential; a rational adjunct for presynaptic CMS given the mechanism, though no published data specifically document 3,4-DAP use/response in a SNAP25-CMS/CMS18 patient in the sources reviewed. General CMS caution: fast-channel CMS patients have died when started on 3,4-DAP, underscoring the need for cautious, monitored introduction of this class in any CMS subtype, including this one, until subtype-specific safety data exist. - Salbutamol (albuterol)/beta-2 agonists: Used in other presynaptic/synaptic-basal-lamina CMS subtypes (e.g., COLQ, COL13A1/CMS19) to improve NMJ structure/function; no SNAP25/CMS18-specific outcome data identified in the reviewed literature — response is undocumented for this specific gene. - No pharmacogenomic (PharmGKB/CPIC) guidance specific to SNAP25-CMS drug selection has been published.

Advanced therapeutics: No gene therapy, cell therapy, RNA-based therapy (ASO/siRNA/mRNA), targeted small-molecule, or immunotherapy approach has been developed or trialed for SNAP25-CMS. Given the dominant-negative/neomorphic mechanism (not simple loss-of-function), an allele-selective knockdown strategy (e.g., ASO) would be a mechanistically rational future direction (analogous to other dominant-negative SNARE/channel disorders) but has not been reported.

Surgical/interventional: No disease-specific surgical intervention reported; general supportive orthopedic management of contractures (e.g., serial casting/tenotomy for arthrogryposis-related contractures) may apply per general arthrogryposis management principles, though not specifically documented for a SNAP25-CMS case.

Supportive/rehabilitative care: - Respiratory support (mechanical ventilation) is critical in severe neonatal presentations and was central to the (unsuccessful) management of the Q177Ter case. - Physical therapy, occupational therapy for contracture management and motor/ataxia-related functional impairment. - Antiepileptic drug management for the seizure component — the index patient's seizures were noted as poorly responsive to valproic acid between ages 5-8, indicating this population may include drug-resistant epilepsy requiring individualized anticonvulsant selection (general DEE-management principles would apply — e.g., broader-spectrum agents, possible ketogenic diet consideration — though no SNAP25-specific antiepileptic-response data were identified). - Speech/communication therapy for patients with absent/impaired speech.

Experimental treatments: No registered clinical trials (ClinicalTrials.gov) specific to SNAP25-CMS/CMS18 were identified in this research.

Treatment outcomes/response rates: No systematic response-rate data exist given the case-report-level evidence base; anecdotal partial response to neostigmine in one patient is the only quantified pharmacologic response documented in the reviewed literature.

Treatment strategy/algorithm: No SNAP25-CMS-specific treatment algorithm exists; management follows general presynaptic-CMS principles (trial of AChE inhibitor ± 3,4-DAP, with caution regarding drugs known to worsen NMJ transmission — see below) combined with standard DEE/epilepsy management and multidisciplinary supportive care (respiratory, orthopedic, developmental).

Drugs to avoid in CMS generally (applies to CMS18 by extension): Ciprofloxacin, chloroquine, procaine/local anesthetics of that class, lithium, phenytoin, beta-blockers, procainamide, and quinidine are flagged in GeneReviews as agents that can exacerbate neuromuscular transmission defects across CMS subtypes and should be used cautiously if at all.

NCIT term suggestions: Pharmacotherapy (NCIT:C15986); the specific AChE-inhibitor and 3,4-DAP mechanisms would be captured via therapeutic_agent (CHEBI terms for pyridostigmine, neostigmine, amifampridine/3,4-DAP, salbutamol) rather than a distinct NCIT action term beyond generic pharmacotherapy.

13. Prevention

Primary prevention: Not applicable — as a de novo dominant disorder with no identified environmental trigger, there is no primary-prevention strategy (no vaccination, risk-factor modification, or avoidable exposure relevant to causation).

Secondary prevention/screening: No population or targeted screening program exists. Prenatal diagnosis (via chorionic villus sampling/amniocentesis with targeted variant testing) could be offered in the rare scenario of a family with a previously molecularly confirmed affected child, given the small but nonzero possibility of parental germline mosaicism, though this has not been formally quantified for SNAP25.

Genetic counseling: Recurrence risk for future pregnancies in a family with one affected child is expected to be low but not zero (consistent with de novo dominant disorders generally, accounting for the possibility, though unconfirmed for SNAP25, of low-level parental germline mosaicism); genetic counseling should convey this general de novo-dominant recurrence framework (typically quoted in the 1-2% range for de novo dominant conditions generically, pending disorder-specific data) rather than the ~25%/50% Mendelian recurrence risks that apply to recessive/dominant-inherited CMS subtypes.

Public health/behavioral interventions: Not applicable — no modifiable behavioral, dietary, or environmental risk factor has been identified for this monogenic disorder.

Prophylaxis: Not applicable.

14. Other Species / Natural Disease

Taxonomy: No naturally occurring SNAP25-related myasthenic/encephalopathic disease has been reported in non-human species (companion animals, livestock, or wildlife) in the literature reviewed. SNAP25 orthologs are highly conserved across vertebrates (human SNAP25 gene ID 6616; mouse ortholog Snap25, MGI:98331; conservation extends to Drosophila and yeast, as reflected in the cross-species functional-domain conservation discussed below).

Natural disease/veterinary relevance: Not documented — no OMIA (Online Mendelian Inheritance in Animals) entries or veterinary case series for spontaneous SNAP25-associated disease were identified.

Comparative biology/evolutionary conservation: The SNARE-complex fusion mechanism disrupted in CMS18 is deeply evolutionarily conserved — the yeast SNAP25 homolog SEC9 shows an analogous temperature-sensitivity phenotype when an equivalent coiled-coil domain mutation is introduced, and Drosophila SNAP-25 mutants (SNAP-25ts, Gly50→Glu in the first amphipathic helix) similarly destabilize SNARE complex thermal stability and produce temperature-dependent neurotransmission defects — directly supporting the human dominant-negative destabilization mechanism proposed for I67N.

Transmission: Not applicable — non-communicable monogenic disorder, no zoonotic or cross-species transmission relevance.

15. Model Organisms

Mouse models: - Snap25 null (knockout) mice: Homozygous null is embryonic/perinatal lethal — Snap25⁻/⁻ mice die at birth due to failure of evoked (calcium-triggered) neurotransmitter release, while spontaneous release persists, directly demonstrating SNAP25's essential, non-redundant role in fast synchronous synaptic vesicle exocytosis (the same biochemical process disrupted by the human dominant-negative/neomorphic disease variants). Heterozygous Snap25⁺/⁻ mice survive to adulthood and are fertile, showing relatively mild behavioral phenotypes (notably hypoactivity) — a haploinsufficiency model that is mechanistically distinct from (and phenotypically milder than) the human dominant-negative disease alleles, illustrating that the human disease variants are not simple loss-of-function/dosage models. - "Blind-drunk" mouse (Snap25 I67T, or per some literature descriptions "S187A"-adjacent regulatory-domain models): A dominant, spontaneous Snap25 point mutation (I67T — note the striking similarity to the human I67N disease variant, affecting the identical residue) causes impaired vesicle trafficking, abnormal sensorimotor gating, and ataxia in heterozygous mice — a close phenotypic and molecular parallel to human CMS18/DEE117, providing strong cross-species validation that mutation at this specific SNAP25 residue produces a dominant, SNARE-destabilizing, ataxia-associated phenotype. This model has additionally been used to study impaired pancreatic beta-cell granule exocytosis and psychiatric/schizophrenia-relevant endophenotypes (impaired sensorimotor gating), reflecting SNAP25's broader dense-core-vesicle exocytosis role beyond classical fast synaptic transmission. - Region/cell-type-specific conditional Snap25 deletion models (e.g., cortical-projection-neuron-specific loss) have been used to dissect circuit-specific consequences relevant to the cortical hyperexcitability/epilepsy component of the human phenotype, and brain-specific SNAP-25 deletion models show elevated extracellular glutamate and schizophrenia-like behavior, offering a partial model for the CNS excitability phenotype.

Invertebrate models: - Drosophila SNAP-25ts (temperature-sensitive paralytic mutant, Gly50→Glu): demonstrates that SNARE complex assembly/disassembly cycling is required for synaptic exocytosis; the mutant SNARE complex is thermally unstable at 37°C (dissociates), producing temperature-dependent facilitation (increased release at permissive temperature) followed by failure of release (restrictive temperature) — mechanistically informative for understanding how discrete point mutations destabilize the SNARE bundle, directly analogous to the human I67N dominant-negative mechanism. - Yeast SEC9 (SNAP25 homolog): an equivalent coiled-coil domain mutation confers temperature sensitivity, underscoring deep conservation of this structural mechanism across ~1 billion years of eukaryotic evolution.

Cellular/in vitro models: - PC12/chromaffin cell transfection systems: Used to directly test human disease-variant SNAP25 constructs for dominant-negative effects on catecholamine (dense-core vesicle) release — the I67N mutant reduced release to 11% of wild-type when cotransfected with wild-type protein, the key functional evidence establishing dominant-negative pathogenicity for this variant in a human-relevant expression system. - Reconstituted liposome/membrane-fusion assays and single-vesicle content-mixing assays: Used extensively (Shen et al. 2014; the 2024 eLife biophysics study) to directly measure the effect of purified mutant SNAP25 protein on calcium-triggered SNARE-mediated membrane fusion kinetics, priming, and the energy landscape of vesicle fusion — the most mechanistically granular data source available for this disease, distinguishing the dominant-negative (I67N) mechanism from the neomorphic gain/loss-of-function (V48F, D166Y) mechanism at a biophysical level. - Cultured neuron electrophysiology (mEPSC/EPSC recordings): Used to characterize the V48F, D166Y, and I67N variants' distinct effects on spontaneous miniature release frequency, evoked EPSC amplitude, and readily-releasable-pool size in central-synapse-relevant neuronal culture systems.

Model recapitulation/limitations: The mouse and Drosophila models recapitulate the core presynaptic exocytosis defect and, in the case of the blind-drunk I67T mouse, the ataxia/sensorimotor phenotype with notable fidelity to the analogous human I67N variant. However, no existing animal model fully recapitulates the combined myasthenic + epileptic-encephalopathy + intellectual-disability phenotype seen in human CMS18 patients within a single system, and the complete embryonic/perinatal lethality of the full null mouse model limits its use for studying postnatal disease progression — heterozygous point-mutant "knock-in" models (blind-drunk I67T; other knock-in efforts referenced in the literature) are therefore the most translationally relevant available resource, though systematic characterization of NMJ-specific (as opposed to CNS) phenotypes in these models is not comprehensively reported in the sources reviewed.

Summary of Key Evidence Citations

Sources: - Entry - #616330 - DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 117; DEE117 - OMIM - Entry - *600322 - SYNAPTOSOMAL-ASSOCIATED PROTEIN, 25-KD; SNAP25 - OMIM - Congenital myasthenic syndrome 18 - NIH Genetic Testing Registry (GTR) - Congenital myasthenic syndrome 18 (Concept Id: C4225364) - MedGen - Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability - PMC (PMID 25381298) - Rapid genome sequencing identifies a novel de novo SNAP25 variant for neonatal congenital myasthenic syndrome - PMC - SNAP25 disease mutations change the energy landscape for synaptic exocytosis due to aberrant SNARE interactions - eLife (PMID 38411501) - Congenital Myasthenic Syndromes Overview - GeneReviews (NBK1168) - A dominant mutation in Snap25 causes impaired vesicle trafficking, sensorimotor gating, and ataxia in the blind-drunk mouse - PNAS (PMID 17283335) - Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1 - PMC (for CMS18/CMS19 disambiguation) - SNAP25 gene - GeneCards - NM_130811.4(SNAP25):c.256G>A (p.Gly86Arg) AND Congenital myasthenic syndrome 18 - ClinVar - Two distinct effects on neurotransmission in a temperature-sensitive SNAP-25 mutant - PubMed - Temperature-Sensitive Paralytic Mutations Demonstrate that Synaptic Exocytosis Requires SNARE Complex Assembly and Disassembly - Neuron (PMID 9728921)